Current progress in the study of acute myeloid leukemia

被引:2
|
作者
Yestemirova, G. A. [1 ]
Yessimsiitova, Z. B. [1 ]
Danilenko, M. P. [2 ]
机构
[1] Al Farabi Kazakh Natl Univ, Alma Ata, Kazakhstan
[2] Ben Gurion Univ Negev, Beer Sheva, Israel
来源
关键词
acute myeloid leukemia; cancer; anemia; FLT3; flavopyridol; HDAC inhibitor; PAP; targeted therapy; HEALTH-ORGANIZATION CLASSIFICATION; 2016; REVISION; DIFFERENTIATION;
D O I
10.26577/ijbch-2019-v2-11
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In recent years the rate of malignant diseases has been growing rapidly around the world. The Republic of Kazakhstan, according to international statistics, refers to the countries with moderately high cancer incidence and mortality. Every year approximately thirty thousand Kazakhstani people are diagnosed with cancer. In 2018, 35,753 patients were registered in the country, of which 44.3% were men and 55.7% were women. Cancer mortality over the same period amounts to about 15,000 lives. The cancer incidence rate increased by 8% from 181.2 (in 1999) to 195.7 per 100,000 population in 2019 [1]. Blood cancers are relatively rare diseases but, nevertheless, in Kazakhstan about 7,000 patients with hematopoietic malignancies are currently registered. Therefore, our knowledge of recent advances in hemato-oncology is highly relevant for successful therapy of these malignancies. In this review we provide information on the subtypes, symptoms, diagnosis and treatment of acute myeloid leukemia (AML) - one of the most aggressive blood cancer.
引用
收藏
页码:86 / 92
页数:7
相关论文
共 50 条
  • [1] The progress and current status of immunotherapy in acute myeloid leukemia
    Yang, Dan
    Zhang, Xiuqun
    Zhang, Xuezhong
    Xu, Yanli
    [J]. ANNALS OF HEMATOLOGY, 2017, 96 (12) : 1965 - 1982
  • [2] The progress and current status of immunotherapy in acute myeloid leukemia
    Dan Yang
    Xiuqun Zhang
    Xuezhong Zhang
    Yanli Xu
    [J]. Annals of Hematology, 2017, 96 : 1965 - 1982
  • [3] Acute myeloid leukemia: current progress and future directions
    Hagop Kantarjian
    Tapan Kadia
    Courtney DiNardo
    Naval Daver
    Gautam Borthakur
    Elias Jabbour
    Guillermo Garcia-Manero
    Marina Konopleva
    Farhad Ravandi
    [J]. Blood Cancer Journal, 11
  • [4] Acute myeloid leukemia: current progress and future directions
    Kantarjian, Hagop
    Kadia, Tapan
    DiNardo, Courtney
    Daver, Naval
    Borthakur, Gautam
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    [J]. BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [5] Progress in Acute Myeloid Leukemia
    Kadia, Tapan M.
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge
    Kantarjian, Hagop M.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (03): : 139 - 151
  • [6] Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions
    Su, Long
    Shi, Yuan-Yuan
    Liu, Zeng-Yan
    Gao, Su-Jun
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Progress in the treatment of acute myeloid leukemia
    Ravandi, Farhad
    Burnett, Alan K.
    Agura, Edward D.
    Kantarjian, Hagop M.
    [J]. CANCER, 2007, 110 (09) : 1900 - 1910
  • [8] Medical progress -: Acute myeloid leukemia
    Löwenberg, B
    Downing, JR
    Burnett, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (14): : 1051 - 1062
  • [9] Current treatment of acute myeloid leukemia
    Roboz, Gail J.
    [J]. CURRENT OPINION IN ONCOLOGY, 2012, 24 (06) : 711 - 719
  • [10] Clinical progress in acute myeloid leukemia Preface
    Rowe, Jacob M.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2008, 21 (04) : 597 - 599